Relay Therapeutics, Inc. Common Stock
RLAYRelay Therapeutics, Inc. (RLAY) is a biotechnology company focused on designing and developing precision medicines by integrating advanced computational and experimental methods. The company aims to target dynamic proteins involved in disease processes, particularly in oncology, to create innovative therapies with improved efficacy and safety profiles.
Company News
Relay Therapeutics announced promising phase 2 trial results for zovegalisib in treating vascular anomalies, with a 60% volumetric response rate. The clinical-stage biotech has a well-capitalized position with $642 million in cash, a structured path to market including a planned phase 3 trial in early 2027, and a diversified pipeline. However, as...
Relay Therapeutics priced an underwritten public offering of 22.9 million shares at $12.00 per share, raising approximately $275 million in gross proceeds. The offering is expected to close on May 22, 2026. The clinical-stage biotech company is developing precision medicine therapies, with its lead asset zovegalisib currently in Phase 3 trials fo...
Relay Therapeutics stock surged 7.87% on Wednesday following positive Phase 2 results for zovegalisib, a vascular anomalies treatment, which showed 60% patient response rates at 12 weeks—exceeding analyst expectations. Two analysts raised their price targets (Barclays to $27, Citizens JMP to $21) and maintained buy ratings. The gains were parti...
Relay Therapeutics announced promising Phase 2 clinical data for zovegalisib in treating PIK3CA-driven vascular anomalies, demonstrating a 60% volumetric response rate at 12 weeks with strong safety and tolerability profiles supporting chronic dosing. The drug showed clinical improvement in 89% of patients per investigator assessment and 79% per ...
Relay Therapeutics announced positive clinical data for zovegalisib combined with Pfizer's atirmociclib and endocrine therapy in heavily pre-treated metastatic breast cancer patients, showing 44% ORR with favorable tolerability. The company plans to initiate a Phase 3 frontline trial in early 2027 with a supply agreement in place with Pfizer for ...
